|
Name |
[(1R,2S,3S,5R,6R,8S,10Z,13S,15S,16R,17S)-17-benzyl-6,13-dihydroxy-6,8,15-trimethyl-14-methylidene-7,19-dioxo-4-oxa-18-azatetracyclo[10.7.0.01,16.03,5]nonadec-10-en-2-yl] acetate
|
Molecular Formula | C30H37NO7 | |
IUPAC Name* |
[(1R,2S,3S,5R,6R,8S,10Z,13S,15S,16R,17S)-17-benzyl-6,13-dihydroxy-6,8,15-trimethyl-14-methylidene-7,19-dioxo-4-oxa-18-azatetracyclo[10.7.0.01,16.03,5]nonadec-10-en-2-yl] acetate
|
|
SMILES |
C[C@H]1C/C=C\C2[C@@H](C(=C)[C@H]([C@@H]3[C@@]2([C@@H]([C@H]4[C@@H](O4)[C@@](C1=O)(C)O)OC(=O)C)C(=O)N[C@H]3CC5=CC=CC=C5)C)O
|
|
InChI |
InChI=1S/C30H37NO7/c1-15-10-9-13-20-23(33)17(3)16(2)22-21(14-19-11-7-6-8-12-19)31-28(35)30(20,22)27(37-18(4)32)24-26(38-24)29(5,36)25(15)34/h6-9,11-13,15-16,20-24,26-27,33,36H,3,10,14H2,1-2,4-5H3,(H,31,35)/b13-9-/t15-,16+,20?,21-,22-,23+,24+,26+,27+,29-,30-/m0/s1
|
|
InChIKey |
WHJRAYUHVRYTTH-CIDHDKDUSA-N
|
|
Synonyms |
19,20-Epoxycytochalasin D
|
|
CAS | NA | |
PubChem CID | 139587836 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 523.6 | ALogp: | 1.9 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 126.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.316 |
Caco-2 Permeability: | -5.237 | MDCK Permeability: | 0.00006770 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.979 |
Human Intestinal Absorption (HIA): | 0.182 | 20% Bioavailability (F20%): | 0.584 |
30% Bioavailability (F30%): | 0.561 |
Blood-Brain-Barrier Penetration (BBB): | 0.277 | Plasma Protein Binding (PPB): | 65.36% |
Volume Distribution (VD): | 1.47 | Fu: | 30.76% |
CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.078 |
CYP2C19-inhibitor: | 0.044 | CYP2C19-substrate: | 0.41 |
CYP2C9-inhibitor: | 0.034 | CYP2C9-substrate: | 0.039 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.12 |
CYP3A4-inhibitor: | 0.797 | CYP3A4-substrate: | 0.348 |
Clearance (CL): | 6.927 | Half-life (T1/2): | 0.785 |
hERG Blockers: | 0.144 | Human Hepatotoxicity (H-HT): | 0.719 |
Drug-inuced Liver Injury (DILI): | 0.93 | AMES Toxicity: | 0.028 |
Rat Oral Acute Toxicity: | 0.383 | Maximum Recommended Daily Dose: | 0.877 |
Skin Sensitization: | 0.094 | Carcinogencity: | 0.211 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.974 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
D0V3ZA | 0.261 | ||||||
D0SP3D | 0.261 | ||||||
D0W7RJ | 0.255 | ||||||
D0D4YZ | 0.255 | ||||||
D01TSI | 0.254 | ||||||
D09NNH | 0.254 | ||||||
D06CWH | 0.253 | ||||||
D0R1BD | 0.246 | ||||||
D0TB8C | 0.240 | ||||||
D01XDL | 0.239 |